Skip to content
Catalyst

OutcomesOutcome

Psoriasis Area and Severity Index (PASI) score

2 findings from 2 compounds ↓reported in points (0-72 scale), or percent change from baseline as recorded with each finding

Psoriasis Area and Severity Index (PASI) score

2 findings · 2 compounds · 2 null · by evidence strength. No dose is advised.

Fig. 2 Psoriasis Area and Severity Index (PASI) score2 compounds outer ring on requestSelected Psoriasis Area and Severity Index (PASI) score · centre
×1.60
Labels
Measured outcomeInspector

Psoriasis Area and Severity Index (PASI) score

Findings drawn, by strength

2findings · 2 compounds

  • Moderate2
Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

Compound no difference foundFindingsStrongest
1
Moderate
1
Moderate

Not pooled · no summary effect · point at a mark · Tab, then the arrow keys

Measured, no difference found2 findings

  1. MelatoninMoved: no difference foundEvidence: ModeratePaper: PMID 385631312024
    Who
    adults with mild-to-moderate plaque psoriasis; melatonin cream 5% w/w vs placebo cream, applied twice daily for 8 weeks
    Dose studied
    melatonin cream 5.0% (w/w) applied twice a day

    Although the PASI score in the melatonin and rosuvastatin groups compared with placebo decreased, the changes were not significant.”

    Quoted verbatim from Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double-blinded clinical trial.RCTPermalink
  2. fish oilMoved: no difference foundEffect, as reportedMD−0.28[−1.74 to 1.19]Evidence: ModeratePaper: PMID 318059112019
    Who
    Patients with psoriasis; three randomized trials, 337 participants, fish oil versus control
    Dose studied
    not reported

    As illustrated in Fig. 3, the meta-analysis found fish oil did not produce significantly greater improvement in the PASI score than the control group (MD − 0.28; 95% confidence interval − 1.74 to 1.19).”

    Quoted verbatim from Effects of fish oil supplement on psoriasis: a meta-analysis of randomized controlled trials.meta-analysisPermalink

How it is measured

Psoriasis Area and Severity Index (PASI), a clinician-scored composite of psoriasis extent and severity across four body regions ranging 0 to 72, reported as the change from baseline to a stated treatment endpoint. Whether the change is reported as an absolute point difference or as a percentage decrease from baseline is recorded with each finding and is not optional: the two are different reported quantities computed from the same underlying instrument.

Measured, with no finding

1 measurement

Show what was measuredHide what was measured
  • Psoriasis Area and Severity Index (PASI) score

    decreases, PASI score reduced from mean 21.57 to 10.77 with FAE after 16 weeks, unchanged with placebo

    Not recorded as a finding: this platform holds no node for the endpoint

    Altmeyer et al. 16 reported a reduction of PASI score from a mean of 21·57 at baseline to 10·77 after 16 weeks of FAE treatment, whereas in the placebo group it remained the same (P < 0·001).

    PMID 27087044 · one of two readings recorded this

Papers about it

As an endpoint3

Show the papersHide the papers
  • Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double-blinded clinical trial.

    Skin research and technology2024PMID 38563131Via: named in the paper, as read

  • Effects of fish oil supplement on psoriasis: a meta-analysis of randomized controlled trials.

    BMC complementary and alternative medicine2019PMID 31805911Via: named in the paper, as read

  • Oral fumaric acid esters for psoriasis: abridged Cochrane systematic review including GRADE assessments.

    The British journal of dermatology2016PMID 27087044Via: named in the paper, as read

Newest

  • Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double-blinded clinical trial.

    Skin research and technology2024PMID 38563131As an endpoint

  • Effects of fish oil supplement on psoriasis: a meta-analysis of randomized controlled trials.

    BMC complementary and alternative medicine2019PMID 31805911As an endpoint

  • Oral fumaric acid esters for psoriasis: abridged Cochrane systematic review including GRADE assessments.

    The British journal of dermatology2016PMID 27087044As an endpoint